The flavored vape problem is still happening

From: POLITICO Pulse - Monday Feb 07,2022 03:08 pm
Presented by PhRMA: Delivered daily by 10 a.m., Pulse examines the latest news in health care politics and policy.
Feb 07, 2022 View in browser
 
POLITICO's Pulse newsletter logo

By Sarah Owermohle

Presented by

PhRMA

Editor’s Note: POLITICO Pulse is a free version of POLITICO Pro Health Care's morning newsletter, which is delivered to our s each morning at 6 a.m. The POLITICO Pro platform combines the news you need with tools you can use to take action on the day’s biggest stories. Act on the news with POLITICO Pro.

QUICK FIX

There’s a loophole in the vape flavor ban, and popular brands like Puff Bar are here for it.

It’s the final appropriations fight for longtime leaders who have top health priorities before them.

HHS Secretary Xavier Becerra heads to Minnesota with First Lady Jill Biden this week.

WELCOME TO MONDAY PULSESomething I read this weekend: The impact we’re just beginning to feel from the diminishing supply of primary care doctors and nurses . Send good reads and tips to sowermohle@politico.com.

 

A message from PhRMA:

Washington is talking about price setting of medicines, but it won’t stop insurers from shifting costs to you. And it will risk access to medicines and future cures. Instead, let’s cap your out-of-pocket costs, stop middlemen from pocketing your discounts and make insurance work for you. Let’s protect patients. It’s the right choice. Learn more.

 
Driving the Day

FLAVORED VAPES ARE BACK — While top tobacco regulators dawdle over the e-cigarette industry’s fate, another class of vape is quietly restocking the market with unregulated, flavored products — and it’s drawing in a growing number of kids, POLITICO’s Katherine Ellen Foley writes.

The problem? To users, these vapes are identical. But because of an obscure loophole, they skirt the Food and Drug Administration’s regulatory umbrella. Unlike traditional cigarette and vape products that contain tobacco-derived nicotine — an addictive stimulant — these vapes contain lab-made nicotine.

That difference puts synthetic vapes beyond the FDA’s reach, which means that manufacturers freely sell fruity- or dessert-flavored products popular among teens. While these products are only legally available to adults over 21, that hasn’t stopped teens before: A 2021 survey from the Centers for Disease Control and Prevention found that 28.6 percent of middle and high school students who vape used a synthetic nicotine brand called Puff Bar.

“Whatever drops in the bucket they’ve made to try to combat youth e-cigarette use, synthetic nicotine has completely undermined it,” Natalie Hemmerich, a senior staff attorney at the Public Health Law Center, who focuses on federal tobacco policy, said.

The FDA insists it’s looking into the issue, but it’s a growing concern for antismoking advocates and lawmakers.

Puff Bar pivoted to synthetic — or tobacco-free — nicotine in early 2021, after the FDA ordered it to stop selling its tobacco-derived flavored products in 2020.

The backstory: Patrick Beltran, the chief executive officer and co-founder of Puff Bar, said the move is meant to serve their adult customers looking for an alternative to cigarettes.

“Adults like the flavors,” he said. “Just because we have flavors doesn’t necessarily mean that we’re marketing to kids.”

Beltran said that if kids are using his product, it’s because vendors aren’t checking their age or they’re getting it from someone else.

“It's like kids, now, and how they get alcohol,” he said. “You go to any high school party, there’s gonna be alcohol there.”

THE LAST BATTLE OF GIANTSRetiring Sens.Patrick Leahy (D-Vt.) andRichard Shelby (R-Ala.) are laying 35 years of experience working together on the line, hoping to cut a massive deal on government spending to avoid the string of stopgap funding patches and shutdown threats that have plagued Congress for months.

Few are particularly upbeat about their prospects. But if anyone can overcome election-year partisanship, it’s the Appropriations Committee leaders, POLITICO’s Burgess Everett and Jennifer Scholtes write.

“If you wanted the plainest Exhibit A for the argument that it’s a good idea to have members serve a long time together, it’d be these two,” Sen. Chris Coons (D-Del.), a member of the Appropriations panel, said.

The stakes: Leahy and Shelby have just a few weeks to determine whether their negotiations succeed or fail, meaning they would have to keep the government on inefficient autopilot or, in the worst-case scenario, risk a shutdown. Already, another short-term stopgap is in the works to avoid a Feb. 18 shutdown, carving out a bit more time for the crafty senators to cut a deal.

The Senate’s spending leaders have had their spats, including in the past year. Shelby blocked action last fall on funding bills, demanding the two parties first strike a grand deal on overall spending levels.

“They both like to spend money,” Sen. John Cornyn (R-Texas) said. Shelby is “a master negotiator … I’ve watched him buy rugs over in the Middle East. He's really good.”

Next year, a massive shift awaits the exits of Leahy and Shelby, who have served a combined 82 years in the Senate — the vast majority of them together. They will likely be replaced atop the plum spending panel by Sens. Patty Murray (D-Wash.) and Susan Collins (R-Maine).

On Tap

BECERRA AND DR. BIDEN TALK CHILDCARE — The White House announced late Sunday that Health and Human Services Secretary Xavier Becerra would join First Lady Jill Biden in a Minnesota visit Wednesday to highlight the American Rescue Plan’s childcare funding.

Why it matters: A slew of reports suggest that the HHS secretary has been sidelined from top health care strategy and that the White House has even considered replacing him, as The Washington Post reported last week.

Becerra hasn’t been as tapped into Covid-19 policy and messaging as “white coats” like Biden chief medical adviser Anthony Fauci or CDC Director Rochelle Walensky, both technically reporting to the HHS director but working directly with the White House. The former California attorney general and longtime lawmaker has instead been launched on other thorny issues like care for migrant children at the border.

Meanwhile: Becerra told CNN’s Edward-Isaac Dovere that he’s amping up his role in the federal Covid-19 response amid confusing messaging and public frustration.

 

A message from PhRMA:

Advertisement Image

 
Around the Agencies

FDA RESTARTING INSPECTIONS — The agency said Friday it will resume standard domestic surveillance inspections this week owing to the declining number of Covid-19 infections across the nation.

FDA staff have relied on remote tools and record requests in lieu of in-person inspections to maintain visibility into regulated firms, POLITICO’s David Lim reports. But the pause of most inspections has been particularly disruptive to certain drug firms that need an in-person visit to bring products to market.

Around the Nation

CALIFORNIA’S NEW COVERAGE PLAN COULD RESHAPE ENROLLMENT — A new deal between California and Kaiser Permanente would allow the insurer to restrict enrollment in the state’s Medi-Cal managed care program — a controversial move some health plans are calling unfair, POLITICO California’s Victoria Colliver writes.

What’s happening: The proposed contract would extend Kaiser’s ability to limit enrollment mainly to previous members in all 32 counties.

The state is renegotiating its Medi-Cal managed care contracts for the first time statewide, with an eye to improving quality of care and reducing health inequities. The five-year contracts are set to begin Jan. 1, 2024.

But also: California is embarking on a massive overhaul of its Medi-Cal program through an initiative known as CalAIM, which is designed to improve the health of the state’s most vulnerable residents. The initiative would better coordinate mental and physical health care and incorporate a variety of nontraditional medical services such as housing, food and peer support. California also plans to extend Medi-Cal to undocumented residents of all ages.

NYC MAYOR BACKS RETIREE HEALTH PLAN — City mayor Eric Adams plans to move forward with a controversial health coverage overhaul for retired city workers, backing the cheaper plan after earlier criticism, POLITICO New York’s Erin Durkin reports.

Adams had been critical of the proposal (made under former Mayor Bill de Blasio) before taking office and said he would reevaluate it, even as it’s stuck in court battles. His support is a pivot: “I believe the new program will be in the best interest of retirees and the city’s taxpayers, who stand to save $600 million annually,” he said in a Sunday statement.

Background: The health care overhaul would affect about 250,000 retired city workers, shifting them to a new plan called Medicare Advantage Plus. They could choose to opt out, but they would have to pay $191 a month to keep their current coverage.

Around the World

THE WAR ON DRUGS AIMS AT CHINA — The deadliest issue in the U.S.-China relationship right now isn’t the potential for military conflict over Taiwan, but the thousands of overdose deaths in the U.S. each year from illicit fentanyl made from Chinese raw materials, POLITICO’s Phelim Kine writes.

What’s happening: China’s reluctance to tighten controls on chemical production and exports has spurred a clash with U.S. legislators. A long-awaited report to be released Tuesday will focus on China’s role in fueling the flow of drugs that Mexican cartels process into synthetic opioid fentanyl.

The report, from the Commission on Combating Synthetic Opioid Trafficking , must also contend with Beijing’s politicizing of counternarcotics cooperation with the U.S., which has stymied efforts to reduce the supply of fentanyl and related chemicals flooding U.S. streets.

CDC data says fentanyl killed more than 64,000 Americans from April 2020 to April 2021. That’s part of a worsening U.S. opioid crisis that’s seen record-high overdoses and deaths during the pandemic.

Names in the News

Susan Dentzer will be the new president and CEO of America’s Physician Groups. Dentzer, who will take the post in March, is currently a senior policy fellow at the Robert J. Margolis Center for Health Policy, where she has focused on payment reforms and value-based care. She’s also chair of the board of directors at Research!America.

Bakul Patel starts this week as the chief digital health officer of global strategy and innovation at the FDA. Patel has spent more than a decade with the agency handling digital health initiatives and medical device policy.

What We're Reading

The Daily Mail’s Georgia Edkins reports that British scientist Sir Jeremy Farrar will be interviewed by the House Committee on Oversight and Reform over his Covid-19 origin theories.

Mask policies for young children in childcare facilities “can be an important component of risk mitigation strategies” when vaccines aren’t available, scientists write in JAMA Open.

 

A message from PhRMA:

Washington is talking about price setting of medicines, but it won’t stop insurers from shifting costs to you. And it will risk access to medicines and future cures. Instead, let’s cap your out-of-pocket costs, stop middlemen from pocketing your discounts and make insurance work for you. Let’s protect patients. It’s the right choice. Learn more.

 
 

Follow us on Twitter

Tucker Doherty @tucker_doherty

Dan Goldberg @dancgoldberg

Erin Banco @ErinBanco

Katherine Ellen Foley @katherineefoley

Lauren Gardner @Gardner_LM

Ben Leonard @_BenLeonard_

Rachael Levy @rachael_levy

David Lim @davidalim

Megan Messerly @meganmesserly

Alice Miranda Ollstein @aliceollstein

Sarah Owermohle @owermohle

Carmen Paun @carmenpaun

Darius Tahir @dariustahir

Megan R. Wilson @misswilson

 

Follow us

Follow us on Facebook Follow us on Twitter Follow us on Instagram Listen on Apple Podcast
 

To change your alert settings, please log in at https://www.politico.com/_login?base=https%3A%2F%2Fwww.politico.com/settings

This email was sent to by: POLITICO, LLC 1000 Wilson Blvd. Arlington, VA, 22209, USA

Please click here and follow the steps to .

More emails from POLITICO Pulse

Feb 04,2022 03:02 pm - Friday

Fauci might as well be running for office

Feb 02,2022 03:04 pm - Wednesday

Getting blunt on Biden’s FDA pick

Feb 01,2022 03:02 pm - Tuesday

Biden to launch ‘long-form’ Moonshot

Jan 27,2022 03:02 pm - Thursday

Breyer’s retirement sets high Senate stakes

Jan 25,2022 03:02 pm - Tuesday

Biden pleas for BBB

Jan 24,2022 03:02 pm - Monday

Rethinking our approach to a pandemic